Antibody-based medicines that target vascular endothelial growth factor (VEGF) are administered by intravitreal injection (IVI) to treat chronic neovascular retinal diseases. Much ongoing effort is focussed on enhancing therapeutic outcome of these medicines. One strategy is the use of dual-acting drugs (e.g., bispecific antibodies) to simultaneously bind to more than one intraocular biological target. A dual-acting molecule targeting components within the vitreal cavity could also extend vitreous residence time. In this review, we describe the applications of bispecific antibodies within the eye, with consideration of potential targets, applications, and suitable bispecific formats.

以血管内皮生长因子 (VEGF) 为靶点的基于抗体的药物通过玻璃体内注射 (IVI) 给药，以治疗慢性新生血管性视网膜疾病。许多正在进行的努力集中在提高这些药物的治疗效果上。一种策略是使用双作用药物（例如，双特异性抗体）同时与一种以上眼内生物靶标结合。玻璃体腔内的双作用分子靶向组分也可以延长玻璃体停留时间。在这篇综述中，我们描述了双特异性抗体在眼内的应用，同时考虑了潜在的目标、应用和合适的双特异性形式。